SCHEMBL6740536

SCHEMBL6740536

CCCCc1oc2ccccc2c1/C=C\c1ccc(OC)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49
CYP2C9 P11712 2/20 0.46
MAOB P27338 1/20 0.44
TRPA1 O75762 1/20 0.44
PTPN1 P18031 3/20 0.44
EYA3 Q99504 1/20 0.44
NR1H4 Q96RI1 1/20 0.43
KDM5A P29375 1/20 0.43
KDM7A Q6ZMT4 1/20 0.43
SIRT3 Q9NTG7 3/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
AHR P35869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735785 1.00 MEN1 (0.60) MEN1KMT2ANPC1MAPTMAPK1
SCHEMBL6735780 1.00 MEN1 (0.60) MEN1KMT2ANPC1MAPTMAPK1
SCHEMBL7800409 0.76 PTPN1 (0.72) NPC1MAPTRAB9ACYP2C9MAOB
SCHEMBL29736895 0.76 EYA3 (0.76) CYP2C9PTPN1EYA3NR1H4KDM5A
SCHEMBL9591605 0.76 EYA3 (0.76) CYP2C9PTPN1EYA3NR1H4KDM5A
SCHEMBL6734640 0.75 PTPN1 (0.55) CYP2C9PTPN1EYA3NR1H4KDM5A
SCHEMBL11614959 0.75 CYP2C9 (0.47) MEN1KMT2ACYP2C9PTPN1EYA3
SCHEMBL1856963 0.74 PTPN1 (0.52) PTPN1EYA3NR1H4L3MBTL1
SCHEMBL9359176 0.72 SIRT3 (0.51) MEN1KMT2AMAPTMAPK1CYP2C9
SCHEMBL38663749 0.72 TRPA1 (0.70) MEN1KMT2ANPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 US disclosed
US-6451845-B1 ANTIDIABETIC AGENTS WYETH 2002-09-17 US disclosed
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-03-21 US disclosed
US-6248764-B1 ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT AMERICAN HOME PRODUCTS CORPORATION 2001-06-19 US disclosed
US-6103708-A USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 MEN1 3814/4885KMT2A 3622/4885NPC1 683/4885
US-20020035272-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia INSR, GPR119, FFAR3 MEN1 3935/4885KMT2A 3202/4885NPC1 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.